Cosmo Pharmaceuticals Appoints New CFO: A Fresh Perspective on Growth and Innovation

Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) has announced the appointment of Giovanni Di Napoli as its new Chief Financial Officer, effective from 24 May 2024. This strategic move brings a wealth of experience and a fresh perspective to the company, poised to drive growth and innovation in the pharmaceutical and healthtech sectors.

Giovanni Di Napoli joins Cosmo Pharmaceuticals from Medtronic, where he held various leadership positions since 2008. Most recently, he served as President of Medtronic's Endoscopy Operating Unit, responsible for one of the most innovative and fast-growing portfolios in the endoscopy market. His impressive track record of global business leadership achievements, highlighted by his transformative tenure at Medtronic, sets the stage for a new era of excellence at Cosmo Pharmaceuticals.


One of Di Napoli's key priorities will be to leverage his international partnerships and collaborations to enhance Cosmo Pharmaceuticals' global presence and competitiveness. His strategic vision, honed by years of collaboration with industry partners and clinicians, will be instrumental in driving business growth, innovation, and establishing robust international partnerships.


Another critical aspect of Di Napoli's role will be addressing potential challenges in his new position. He anticipates that the dynamic nature of the pharmaceutical and healthtech industries may present obstacles, but his proven ability to foster talent, drive growth, and spearhead innovation will be invaluable in overcoming these hurdles. By working closely with the team and understanding the potential of Cosmo Pharmaceuticals' business, Di Napoli aims to accelerate the company's path forward and build on its legacy as a trusted leader in pharma and healthtech innovation.

In conclusion, the appointment of Giovanni Di Napoli as the new CFO of Cosmo Pharmaceuticals signals a fresh perspective on growth and innovation. His extensive experience, strategic vision, and ability to navigate challenges make him an ideal fit for the role. As Cosmo Pharmaceuticals continues to thrive under his leadership, investors can expect a renewed focus on global expansion, strategic partnerships, and a commitment to driving the company's mission to improve patients' care.